SurModics Financial Statements
SurModics Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | September |
| Annual Report | Company Web Site |
| Investor Relations | Company Web Site |
This data is provided as per license from EDGAR Online
SurModics Income Statement
| 2007 | 2006 | 2005 | |
|---|---|---|---|
| Revenue ($ mil.) | 73.2 | 69.9 | 62.4 |
| Gross Profit ($ mil.) | 67.6 | 46.1 | 59.5 |
| Operating Income ($ mil.) | 9.9 | 36.2 | 3.0 |
| Total Net Income ($ mil.) | 3.3 | 20.3 | (8.3) |
| Diluted EPS (Net Income) | 0.18 | 1.09 | (0.45) |
SurModics Quarterly Statements
| Quarter Ending Jun 08 | Quarter Ending Mar 08 | Quarter Ending Dec 07 | |
|---|---|---|---|
| Revenue ($ mil.) | 24.3 | 25.7 | 23.8 |
| Gross Profit ($ mil.) | 22.5 | 24.4 | 21.0 |
| Operating Income ($ mil.) | 7.2 | 7.2 | 7.6 |
| Total Net Income ($ mil.) | 4.8 | 5.1 | 5.7 |
| Diluted EPS (Net Income) | 0.27 | 0.27 | 0.31 |
SurModics Stock Quote & Chart
12/04/08 16:00:04 EST •
NASDAQ •
21.42
•
 0.0000
•
0.0000 %
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
SurModics Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 3.74 | 2.08 | 0.87 |
| Price/Earnings Ratio | 197.00 | 9.62 | 9.84 |
| Price/Book Ratio | 2.45 | 1.55 | 0.84 |
| Price/Cash Flow Ratio | 7.16 | 8.50 | 5.53 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed SurModics Financial Ratios
SurModics Competitive Intelligence
| Angiotech Pharmaceuticals | Biocompatibles | W.L. Gore | |
|---|---|---|---|
| Annual Sales ($ mil.) | 287.7 | 9.1 | 2,400.0 |
| Employees | -- | 89 | 8,500 |
| Market Cap ($ mil.) | 10.2 | -- | -- |
Competitive Landscape
